Used as a key intermediate in the synthesis of epidermal growth factor receptor (EGFR) inhibitors, particularly in targeted cancer therapies. It plays a critical role in the development of tyrosine kinase inhibitors (TKIs) that are effective against non-small cell lung cancer (NSCLC) with specific EGFR mutations. Its structural configuration enables selective binding to mutant forms of EGFR, enhancing therapeutic efficacy while minimizing effects on wild-type receptors. This compound is primarily utilized in pharmaceutical research and development for oncology drugs, especially in creating third-generation inhibitors that overcome common resistance mutations like T790M.